{"name":"Olema Pharmaceuticals","slug":"olema","ticker":"OLMA","exchange":"NASDAQ","domain":"olema.com","description":"Olema Pharmaceuticals is a biotechnology company focused on developing innovative therapies for cancer treatment. The company's pipeline includes several promising candidates, including OLMA-073, a selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer. With a strong focus on oncology, Olema Pharmaceuticals is well-positioned to capitalize on the growing demand for targeted cancer therapies. The company's pipeline and partnerships position it for long-term growth and success.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Sean Bohen","sector":"Oncology / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$950M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":157697000,"netIncome":-162451000,"cash":533430000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"OLMA-073 patent cliff ($0.00 at risk)","drug":"OLMA-073","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"trial","headline":"Olema Pharmaceuticals Announces Positive Topline Results from Phase 1 Clinical Trial of OLMA-073","summary":"Olema Pharmaceuticals announced positive topline results from its Phase 1 clinical trial of OLMA-073, a selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer.","drugName":"OLMA-073","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"Olema Pharmaceuticals Enters into Collaboration and License Agreement with Pfizer","summary":"Olema Pharmaceuticals entered into a collaboration and license agreement with Pfizer to develop and commercialize OLMA-073, a selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer.","drugName":"OLMA-073","sentiment":"positive"}],"realNews":[{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQ3FiT0d4YUgtMmExU0JKbkhDNm45NGJXd0dSM3pVWHdTRUI1QmYzdDQxUllISHgxemQ3eUVKMHBmbTRKSnBnTTJxeDNqUDFHOWk0eXdXNGhJbzB0U3VBM0lhbklIM3RrY2NHYVBYZVN2NG1LQi16c0JiTHhKcmExT0dITDdUcDUyM00xMUNCdFJlOGlpUi1nRm5UcDNFWExhZjRkekhVMVhMUGpfOTNmcEg4Y2lKU19jOHdmZFdOQzFDUQ?oc=5","date":"2026-01-14","type":"regulatory","source":"Investing.com","summary":"Olema Pharma ch. discov. Myles sells shares worth $2.97 million - Investing.com","headline":"Olema Pharma ch. discov. Myles sells shares worth $2.97 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRUFRX0NXdGRmYUM4bkgtbW14bHRTbVdXOWZ6ZjVmRkNONjc5bHlCYXQya3BSb2F6QjJONFd0SE0teWZQSlFYVkx0TnhtamxJUHBGLUVmLVdCdllPSXFRSzd6NFpVR041ZEFoeHBzc1NqTmpXZ2ZxdU95d3NRWlE4VXgwQmVaREh0R3A3SElPSEFvU2o5VGh2SUZwbHNZdXRuZjFwLXBmRHpXd1BPaE1zOXFZdDR3dDR0ODlMMkJPSGo?oc=5","date":"2025-12-10","type":"regulatory","source":"TechStock²","summary":"Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know - TechStock²","headline":"Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWXpnQmo2ekFMVmM3YzZKMGVnZVJ4MVZkX21TRjRRcFJuN1FEOTVIYmVVNWlmS2IteTdCM25XX1hKRk9raEpYWEEzXzF5ODhOeFlsTjZ5N2I1aVJiblVBNHBFSDVndHJVUlVPQkxnM3RsQ0h4aEx3TnNHRkZfLTNvWmdxTVJHTjd2QTlsQ1RrdmNLbmVNNXNtYzBvMG9WZw?oc=5","date":"2025-11-19","type":"regulatory","source":"CoinCentral","summary":"Olema Pharma (OLMA) Stock Drops as Company Announces Public Offering Plans - CoinCentral","headline":"Olema Pharma (OLMA) Stock Drops as Company Announces Public Offering Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPeERPYnpKQWdoSVpPQjlBNlRuRldMajh4aDV2MnhVUkhuczVOV3AyamdaX2M3Z3hINjVIQ09UNXdjZThlNjJpbEZBZGZZcXB3cU5QeldjZ3JXalQyanlhSGw5aXJ2bHZlMmItVTlhQWdEMHRJLVowMGU3aDdZVGcwOTVHblZoRlV4VlRCRDVBWUlyTWtDVVpYR2NoTm9OOE1QdFBiWVZhOWtNOURkaU9WSnpR?oc=5","date":"2025-11-19","type":"regulatory","source":"Seeking Alpha","summary":"Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution (NASDAQ:OLMA) - Seeking Alpha","headline":"Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution (NASDAQ:OLMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQWVllTzg0SGFtOHZoV1podUt3YUgwOGNfY1I4Zml3dFBydGhBLTNULUhENHlnbWViWUxJajJpWER3UDZRVS1NcWVfVjN1aDhvVXFrTW9OY0FTc2ZCamJ2alZNUXNsYVNieHFHYjVWUkNTMG5HcG1ZWkVLWG1YU1lFX2dlWm41NTU1Z1F0MEtTaHdFMkd5THVlT1hjWnphd2hpYlc5N1ByVkVtU21UZ0h1bmk0MDU5b1pHc3c?oc=5","date":"2025-11-18","type":"trial","source":"Investor's Business Daily","summary":"Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily","headline":"Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNUmJESmd0VXB1cVNMUkg2SklsZm9JdURSNHZQVEhpVFlqR2R1MlpXdUc4THhzTmdMam1OZXhBYzdKcjJPQTlmQVVaNzBiRXZUV1JGTmx2M0dFNG5DbVhqbGZkY1JCZkpkb05tVndnVGowb3pyaWt1QzZwWC1UV2FiR3FmSGp6TzR5M3JOYnktZ1Ywa2RpNVJnUTB5SGJYaXZBR01saEIzRDhZTnlPRTlWT3NUcWk2bEhDU1hDSQ?oc=5","date":"2025-11-18","type":"regulatory","source":"Quiver Quantitative","summary":"Olema Pharmaceuticals Stock (OLMA) Opinions on Strategic Collaboration Announcement | OLMA Stock News - Quiver Quantitative","headline":"Olema Pharmaceuticals Stock (OLMA) Opinions on Strategic Collaboration Announcement | OLMA Stock News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNckdHM2hWOHhWYmJfQ1RjU25MZFZ4ck1yc05oQmhsNGtsUXViMnJuVGpnVVp5ZTQxRF9YNkpWVEFsYVBGS2Q3Mzc3eGtxTTRmbVpaNDRzU3RnZ1dYLUh6UEhrTFhRX0loam41M0tnUXZvSVZMUmRpUERuNkNkTDk0ckJFYUw?oc=5","date":"2025-11-18","type":"regulatory","source":"TipRanks","summary":"Why Is Olema Pharmaceuticals Stock (OLMA) Up Today? - TipRanks","headline":"Why Is Olema Pharmaceuticals Stock (OLMA) Up Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVjZSSE1sN20yaGhCUlMwRUw2Q1c3dlNtMWIyNXE2ZUVvcFJPalNONmgtX2cwd2s2OGlUTjZVUEFHQmJIUEdiMkdvZTBNbkg1UV9SY2dZVEFHQVBhQ0xaTldfQzItcEdSRUtoTzN6RURpTGtIUXB3ay1LNmJYVHZib0hIWDFZdjBYSEUySk5hb0ZzNHJCRVpCUWF3T0tCcHhWd2lfTmxPanBqTlNSRzIwaDBnYURTODdVTkY4?oc=5","date":"2025-11-18","type":"regulatory","source":"Benzinga","summary":"Why Is Olema Pharmaceuticals Stock Soaring Today? - Olema Pharmaceuticals (NASDAQ:OLMA), Roche Holding (O - Benzinga","headline":"Why Is Olema Pharmaceuticals Stock Soaring Today? - Olema Pharmaceuticals (NASDAQ:OLMA), Roche Holding (O","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQcFltdnlUa1BZNnJBUWVrUl81TFp4dkgxb2hROVhfckdSdFN5aHMxSHhQTGs0YVJvdFcxWHhOLUxoRXF0VnI1TjhvVmp0UlFDOVpLQVZKUlh5SllxVVpNYW9jeGpkNGRPeVRyMmZxMzlMX1UxR3FNV0JTR0J5Z09xTjFtdk1FNUdMM2l4WjBsUElleTBrT1E?oc=5","date":"2025-11-18","type":"pipeline","source":"Invezz","summary":"OLMA stock: could today’s 197% surge be just the beginning? - Invezz","headline":"OLMA stock: could today’s 197% surge be just the beginning?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNak5TOTFXX0hVS2xPR2NCQUVrYjRFaWZzVWxUc2ZPR0ctdG0tMjFySHpwMTA2TXRWZ3pBQ2VEZXlJdnZkV3RnRUdtbEwwTG16dFVDNWhwcGF1cjl3aFp4TzBadU1RSl9ualZLbGtEcGctR1M0dmRhQzNZdkVYdlROMGNPZWpSeW1aU3BEbmJqeGlFLWxLQkZiMEk3Uy10YUk?oc=5","date":"2025-10-21","type":"regulatory","source":"Seeking Alpha","summary":"Olema Pharmaceuticals: Tapping The Brakes (Rating Downgrade) (NASDAQ:OLMA) - Seeking Alpha","headline":"Olema Pharmaceuticals: Tapping The Brakes (Rating Downgrade) (NASDAQ:OLMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNTlZ6UWRJbXBocldieS1yckJwcHFwNDlIYW1xbWJ3THMyN2drdm96cDZzc2Z5dFYwX2NBc3pubm5UbGlzaE1XWW1pVDZXNU9Qb1JZV1BDTzh4aXdUejRrLWpuc2otRmJlYVpwbkJ0UmxqUmVkbVV2ZVZ5X0N2elU2cGctV1I?oc=5","date":"2025-09-30","type":"regulatory","source":"Yahoo Finance","summary":"Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Yahoo Finance","headline":"Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPUnNPMFVBRU9Dd0tUS0s5VGFtVUY0akZMenlxbU9qb0xSVEd6RVN5UXIzQW56X0FOQlAxLXlJTXVGREIyWC1NTU14d2xUTDh0cnVYd3NuNHpXQ2JoRkFfMC1ybmdOQXZOdURxb1JndUNYckNGZTItVUhtVHRrbG03YW05cm1RUzdmZTBHZ1A0cHdOZVJnNG1LUTVCYjZRTlhKUGNOVw?oc=5","date":"2025-09-17","type":"regulatory","source":"RTTNews","summary":"Olema Pharma In Focus Ahead Of Key Data Presentation At ESMO 2025 - RTTNews","headline":"Olema Pharma In Focus Ahead Of Key Data Presentation At ESMO 2025","sentiment":"neutral"}],"patents":[{"drugName":"OLMA-073","drugSlug":"selective-estrogen-receptor-degrader-(serd)","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Eli Lilly","AstraZeneca"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":157697000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-162451000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":533430000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}